文献速递基础与转化研究临床试验与 GCP真实世界研究与卫生经济

同种异体间充质干细胞联合自体软骨细胞移植一期修复膝关节局灶性软骨缺损的随机交叉对照试验研究方案

Efficacy of one-stage cartilage repair using allogeneic mesenchymal stromal cells and autologous chondron transplantation (IMPACT) compared to nonsurgical treatment for focal articular cartilage lesions of the knee: study protocol for a crossover randomized controlled trial.
PubMed 文献 · Trials · 2020-10-09

本研究为随机对照试验方案,拟纳入60例膝关节大面积(2-8 cm²)局灶性软骨缺损患者,随机接受非手术治疗或IMPACT手术(快速分离自体软骨细胞联合同种异体间充质干细胞一期移植)。主要比较18个月内KOOS、疼痛NRS和EQ5D-5L评分变化,并评估MRI软骨形成、安全性和成本效果。

要点

  • IMPACT为单期手术,结合快速分离的自体软骨细胞与同种异体MSCs。
  • 对照为非手术治疗,9个月后允许交叉接受IMPACT手术。
  • 主要结局包括KOOS、NRS疼痛和EQ5D-5L,随访至18个月。

核心结论

  • 研究旨在评估IMPACT对比非手术治疗膝关节大面积软骨缺损的疗效、安全性和成本效果。

研究设计与样本

  • 随机对照试验,计划纳入60例膝关节2-8 cm²局灶性软骨缺损患者,随机分入非手术组或IMPACT组。
  • 非手术组治疗9个月后允许交叉接受IMPACT手术。

主要发现

  • 研究方案未报告结果数据。

关键数值与推荐

  • 主要评估指标为KOOS、疼痛NRS和EQ5D-5L,在基线及纳入后3、6、9、12、18个月比较。
  • MRI评估软骨形成于基线及纳入后6、18个月进行。
  • 由独立风湿科医生监测潜在炎症反应,记录(严重)不良事件。
  • 成本效果分析基于医疗资源使用和生产力损失,构建5年时间 horizon 的健康经济模型估算增量成本效果比(每质量调整生命年成本)。

临床怎么用

  • 若验证有效,IMPACT可为一期修复大面积膝关节软骨缺损提供新选择。
  • 研究将提供IMPACT对比非手术治疗的成本效果信息,辅助临床决策。

局限性

  • 研究方案尚未报告实际结果,疗效与安全性结论待验证。
  • 样本量60例,安全性和成本效果评估的统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Articular cartilage defects in the knee have poor intrinsic healing capacity and may lead to functional disability and osteoarthritis (OA). "Instant MSC Product accompanying Autologous Chondron Transplantation" (IMPACT) combines rapidly isolated recycled autologous chondrons with allogeneic MSCs in a one-stage surgery. IMPACT was successfully executed in a first-in-man investigator-driven phase I/II clinical trial in 35 patients. The purpose of this study is to compare the efficacy of IMPACT to nonsurgical treatment for the treatment of large (2-8 cm2) articular cartilage defects in the knee. METHODS: Sixty patients will be randomized to receive nonsurgical care or IMPACT. After 9 months of nonsurgical care, patients in the control group are allowed to receive IMPACT surgery. The Knee Injury and Osteoarthritis Outcome Score (KOOS), pain (numeric rating scale, NRS), and EuroQol five dimensions five levels (EQ5D-5 L) will be used to compare outcomes at baseline and 3, 6, 9, 12, and 18 months after inclusion. Cartilage formation will be assessed at baseline, and 6 and 18 months after inclusion using MRI. An independent rheumatologist will monitor the onset of a potential inflammatory response. (Severe) adverse events will be recorded. Lastly, the difference between IMPACT and nonsurgical care in terms of societal costs will be assessed by monitoring healthcare resource use and productivity losses during the study period. A health economic model will be developed to estimate the incremental cost-effectiveness ratio of IMPACT vs. nonsurgical treatment in terms of costs per quality adjusted life year over a 5-year time horizon. DISCUSSION: This study is designed to evaluate the efficacy of IMPACT compared to nonsurgical care. Additionally, safety of IMPACT will be assessed in 30 to 60 patients. Lastly, this study will evaluate the cost-effectiveness of IMPACT compared to nonsurgical care. TRIAL REGISTRATION: NL67161.000.18 [Registry ID: CCMO] 2018#003470#27 [EU-CTR; registered on 26 March 2019] NCT04236739 [ ClinicalTrials.gov ] [registered after start of inclusion; 22 January 2020].

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Korpershoek JV, Vonk LA, Kester EC, et al. Efficacy of one-stage cartilage repair using allogeneic mesenchymal stromal cells and autologous chondron transplantation (IMPACT) compared to nonsurgical treatment for focal articular cartilage lesions of the knee: study protocol for a crossover randomized controlled trial. Trials. 2020. PMID: 33036661. doi:10.1186/s13063-020-04771-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。